Manufacturer
JOHNSON & JOHNSON SDN BHD
Contents
Abiraterone acetate
Indication
In combination w/ prednisone or prednisolone for treatment of: metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after androgen deprivation therapy (ADT) failure in whom chemotherapy is not yet clinically indicated; mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen; in combination w/ prednisone or prednisolone & ADT in patients w/ newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) who may have received up to 3 mth prior to ADT.
Instruction
Should be taken on an empty stomach: Take at least 1 hr before or 2 hr after meals. Swallow whole do not chew/crush.
Drug interaction
Increased absorption w/ food, strong CYP3A inducers eg, phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarb. Co-administration w/ CYP2D6-activated/metabolised drugs. CYP2C8 substrate w/ narrow therapeutic index.
Malaysia
